Azzolini Elena, Canziani Lorenzo Maria, Voza Antonio, Desai Antonio, Pepys Jack, De Santis Maria, Ceribelli Angela, Pozzi Chiara, Turato Massimo, Badalamenti Salvatore, Germagnoli Luca, Mantovani Alberto, Rescigno Maria, Selmi Carlo
Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
IRCCS Humanitas Clinical Research Hospital, via Manzoni 56, Rozzano, 20089 Milan, Italy.
Vaccines (Basel). 2022 Mar 13;10(3):439. doi: 10.3390/vaccines10030439.
Short-term adverse events are common following the BNT162b2 vaccine for SARS-Cov-2 and have been possibly associated with IgG response. We aimed to determine the incidence of adverse reactions to the vaccine and the impact on IgG response. Our study included 4156 health-care professionals who received two doses of the BNT162b2 vaccine 21 days apart and obtained 6113 online questionnaires inquiring about adverse events. The serum response was tested in 2765 subjects 10 days after the second dose. Adverse events, most frequently a local reaction at the site of injection, were reported by 39% of subjects. Multivariate analysis showed that female sex (odds ratio—OR—1.95; 95% confidence interval—CI—1.74−2.19; p < 0.001), younger age (OR 0.98 per year, p < 0.001), second dose of vaccine (OR 1.36, p < 0.001), and previous COVID-19 infection (OR 1.41, p < 0.001) were independently associated with adverse events. IgG response was significantly higher in subjects with adverse events (1110 AU/mL—IQR 345-1630 vs. 386 AU/mL, IQR 261-1350, p < 0.0001), and the association was more pronounced in subjects experiencing myalgia, fever, and lymphadenopathy. We demonstrate that a more pronounced IgG response is associated with specific adverse events, and these are commonly reported by health care professionals after the BNT162b2 vaccine for SARS-Cov-2.
接种针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的BNT162b2疫苗后，短期不良事件很常见，并且可能与免疫球蛋白G（IgG）反应有关。我们旨在确定该疫苗不良反应的发生率及其对IgG反应的影响。我们的研究纳入了4156名医护人员，他们间隔21天接种了两剂BNT162b2疫苗，并获得了6113份关于不良事件的在线调查问卷。在第二剂疫苗接种10天后，对2765名受试者进行了血清反应检测。39%的受试者报告了不良事件，最常见的是注射部位的局部反应。多因素分析显示，女性（比值比[OR]为1.95；95%置信区间[CI]为1.74-2.19；p<0.001）、年龄较小（每年OR为0.98，p<0.001）、接种第二剂疫苗（OR为1.36，p<0.001）以及既往感染过冠状病毒病2019（COVID-19）（OR为1.41，p<0.001）与不良事件独立相关。发生不良事件的受试者的IgG反应显著更高（1110任意单位/毫升[AU/mL]，四分位间距[IQR]为345-1630，而386 AU/mL，IQR为261-1350，p<0.0001），并且这种关联在出现肌痛、发热和淋巴结病的受试者中更为明显。我们证明，更明显的IgG反应与特定不良事件相关，并且这些不良事件在医护人员接种针对SARS-CoV-2的BNT162b2疫苗后很常见。
